Biologics, spondylitis and COVID-19

The COVID-19 pandemic has been especially challenging for patients with rheumatic diseases because immune-mediated diseases as well as their treatment could adversely impact susceptibility to or severity of a viral infection. A recent study from New York City on 86 patients with COVID-19 infection and a history of immune-mediated disease seemed to show that the use of methotrexate, oral glucocorticoids or hydroxychloroquine increased the risk for hospitalisation, although the authors still concluded that the overall risk for hospitalisation is comparable to that described in the community. Since data to advise patients on these issues are scant and inconclusive, the Spondylitis Association of America (SAA) is conducting a survey to gather information from patient experience.

The SAA contacted by email nearly 40,000 individuals who had previous interaction with the SAA. Between 10 April 2020...
and 7 May 2020, 2992 patients completed an online survey and reported a history of spondylitis confirmed by a physician. The survey had been approved by the Institutional Review Board of the Oregon Health & Science University. The respondents included 85.0% with ankylosing spondylitis and others with additional forms of spondyloarthritis such as psoriatic spondyloarthritis. Of those patients who knew results of human leukocyte antigen (HLA) typing, 76.1% were HLA B27+. The respondents included 1104 men, 1838 women and 8 whose gender was non-binary and 42 not providing gender information. The median age was 53 for women and 54 for men. Eighty per cent were from the USA, while other respondents were from 64 other countries. Two hundred twenty-three (7.6%) of 2950 respondents believed that they had been exposed to COVID-19. Thirty-nine (1.3%) believed that they had been infected with COVID-19 of whom 14 (35.9%) of those with presumed COVID-19 had confirmation by laboratory testing. As not everyone has access to testing for confirmation, we based our analysis on either confirmed or presumed infection as is the current practice of the Oregon Health Authority.

Table 1 and figure 1 analyse patients according to class of medication taken for spondylitis with some individuals taking more than one class. The figure indicates that roughly one in four patients on a biologic (25%) for antitumour necrosis factor (TNF) or 23% for anti-interleukin 17 (IL-17) reduced their medication (either eliminated, reduced the dosage or reduced the frequency) because of concerns about COVID-19. The changes are prior to acquiring the actual infection. The table shows that several of the same medications that are feared to increase susceptibility to COVID-19 (antimalarials, corticosteroids, anti-TNF, anti-IL-17) are actually associated with a rate of COVID-19 lower than or equal to 1.3% for the group as a whole. The reduced likelihood for developing COVID-19 for those taking anti-TNF or an antimalabole is not statistically significant (p>0.05). Ironically, one class of medication that was associated with risk above 1.3% is antimalarials, but too few patients took this class to provide definitive results.

Surveys are not reliable instruments to determine if the disease itself predisposes to infection since there is inherent bias as to who responds to the survey. However, we did obtain a modified Bath Ankylosing Spondylitis Disease Activity Index from respondents and found little correlation between spondylitic disease activity and severity of COVID-19 as graded by days of disease, probability of hospitalisation or subjective scoring of severity (data not shown).

Although our numbers of subjects infected by COVID-19 are small, the trend showing reduced infection for those on anti-TNF or antimalaboles provides reassurance to patients and providers regarding the safety of several classes of medication frequently prescribed to treat spondylitis, psoriasis and other immune-mediated diseases. Our survey is designed to capture longitudinal patient data and data from household contacts. This prospective approach should provide additional, future insight as to how spondylitis and the medications taken for this illness potentially affect susceptibility and severity of COVID-19.

Table 1 Impact of medications on C19

<table>
<thead>
<tr>
<th>Medication class</th>
<th>Number taking</th>
<th>% with C19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aminosalicylates</td>
<td>283</td>
<td>0.7</td>
</tr>
<tr>
<td>Antimalarials</td>
<td>103</td>
<td>3.9</td>
</tr>
<tr>
<td>Antimetabolites</td>
<td>366</td>
<td>0.5</td>
</tr>
<tr>
<td>Biologic (anti-TNF)</td>
<td>1442</td>
<td>0.8</td>
</tr>
<tr>
<td>Biologic (IL-17)</td>
<td>298</td>
<td>1.3</td>
</tr>
<tr>
<td>Corticosteroid</td>
<td>237</td>
<td>0.4</td>
</tr>
<tr>
<td>JAK inhibitor</td>
<td>52</td>
<td>1.9</td>
</tr>
<tr>
<td>NSAID</td>
<td>1594</td>
<td>1.3</td>
</tr>
<tr>
<td>No medication</td>
<td>230</td>
<td>3.5</td>
</tr>
</tbody>
</table>

Number taking includes those who altered the dosage or discontinued the medicine as a result of COVID-19. C19=COVID-19. Per cents are based on those with either definite or presumed COVID-19.

IL-17, interleukin 17; JAK, janus kinase; NSAID, non-steroidal anti-inflammatory drug; TNF, tumour necrosis factor.
Provenance and peer review  Not commissioned; externally peer reviewed.

Data availability statement  The data on which this study are based are available by contacting Hedley Hamilton at Any-3.com.

This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.


Received 13 May 2020
Revised 21 May 2020
Accepted 22 May 2020
Published Online First 10 June 2020


ORCID IDs
James Todd Rosenbaum http://orcid.org/0000-0002-8452-2441
Kevin L Winthrop http://orcid.org/0000-0002-3892-6947

REFERENCES